Metal Drugs and the Anticancer Immune Response
Open accessThe DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Abstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Chattopadhyay, S., Dash, S. K., Mahapatra, S. K., Tripathy, S., Ghosh, T., Das, B., Das, D., Pramanik, P., & Roy, S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1085-2 · Cited by 50
RetractedChatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI · Paper page
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Items 101–200 of 354
Mitochondria‐Targeted Molecular Tools in Precise Tumor Therapy
Wang, X., Tang, Y., & Li, Q. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511230 · Cited by 44
Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy
Zhang, J., Jiang, M., Li, S., Zhang, Z., Sun, H., Yang, F., & Liang, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00050 · Cited by 40
Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer
Tan, Y., Chen, H., Zhang, J., Cai, L., Jin, S., Song, D., Yang, T., Guo, Z., & Wang, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114047 · Cited by 40
Levina, A., Crans, D. C., & Lay, P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040790 · Cited by 39
Zhang, Z., Yu, P., Gou, Y., Zhang, J., Li, S., Cai, M., Sun, H., Yang, F., & Liang, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00939 · Cited by 39
Xu, Z., Lu, Q., Shan, M., Jiang, G., Liu, Y., Yang, Z., Lu, Y., & Liu, W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00063 · Cited by 39
Dichloro Ru(II)-p-cymene-1,3,5-triaza-7-phosphaadamantane (RAPTA-C): A Case Study
Swaminathan, S., & Karvembu, R. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00085 · Cited by 39
Development of Platinum Complexes for Tumor Chemoimmunotherapy
Jin, S., Guo, Y., & Wang, X. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202302948 · Cited by 39
Gold Nanocluster: A Photoelectric Converter for X‐Ray‐Activated Chemotherapy
Chen, F., Ruan, F., Xie, X., Lu, J., Sun, W. C., Shao, D., & Chen, M. (2024) · Advanced Materials · doi:10.1002/adma.202402966 · Cited by 38
Galvez, L., Rusz, M., Schwaiger-Haber, M., Abiead, Y. E., Hermann, G., Jungwirth, U., Berger, W., Keppler, B. K., Jakupec, M. A., & Koellensperger, G. (2019) · Metallomics · doi:10.1039/c9mt00141g · Cited by 39
Self-citationFranich, A. A., Živković, M. D., Tomic, T. I., Đorđević, I., Nikodinović‐Runić, J., Pavić, A., Janjić, G. V., & Rajković, S. (2020) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-020-01770-7 · Cited by 37
Curado, N., Giménez, N., Miachin, K., Aliaga‐Lavrijsen, M., Cornejo, M., Jarzęcki, A. A., & Contel, M. (2019) · ChemMedChem · doi:10.1002/cmdc.201800796 · Cited by 36
Machado, J. F., Correia, J. D. G., & Morais, T. S. (2021) · Molecules · doi:10.3390/molecules26113153 · Cited by 39
“This compound was obtained by conjugation of the fluorescent and cytotoxic complex [Ru(phenSe)2(pbiz)] (phenSe = [1,2,5] selenadiazol [3,4-f ] [1,10]phenanthroline) to a biotin through a hexamethylenedia ine linker.”
BackgroundMethodPei, Z., Li, L., Yang, N., Sun, S., Jiang, N., & Cheng, L. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215969 · Cited by 37
Pei, Z., Jiang, N., Gong, F., Yang, W., Xu, J., Yu, B., Yang, N., Wu, J., Lei, H., Sun, S., et al. (2024) · Materials Today · doi:10.1016/j.mattod.2024.07.013 · Cited by 34
Ruthenium(ii)–Arene Complex Triggers Immunogenic Ferroptosis for Reversing Drug Resistance
Lv, M., Zheng, Y., Dai, X., Zhao, J., Hu, G., Ren, M., Shen, Z., Su, Z. G., Wu, C., Liu, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01467 · Cited by 33
Gao, S., Huang, M., Sun, Z., Li, D., Xie, C., Feng, L., Liu, S., ZHENG, K. C., & Pang, Q. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129096 · Cited by 33
Emerging Metallopharmaceuticals for the Treatment of Cancer
Johnson, A., Northcote‐Smith, J., & Suntharalingam, K. (2020) · Trends in Chemistry · doi:10.1016/j.trechm.2020.10.011 · Cited by 34
Zhou, S., Li, J., Yu, J., Wang, Y., Lin, G., Lin, G., He, Z., & Wang, Y. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111835 · Cited by 33
150 years of the periodic table: New medicines and diagnostic agents
Imberti, C., & Sadler, P. J. (2020) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2019.11.001 · Cited by 32
Metallodrugs for the Treatment of Trypanosomatid Diseases: Recent Advances and New Insights
Navarro, M., Justo, R. M. S., Delgado, G. Y. S., & Visbal, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201113104633 · Cited by 36
Chang, M. R., Matnurov, E. M., Wu, C., Arakelyan, J., Choe, H.-J., Kushnarev, V. A., Yap, J. Y., Soo, X. X., Chow, M. J., Berger, W., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17966 · Cited by 35
Self-citationLozada, I. B., Huang, B., Stilgenbauer, M., Beach, T., Qiu, Z., Zheng, Y., & Herbert, D. E. (2020) · Dalton Transactions · doi:10.1039/d0dt01275k · Cited by 31
Cisplatin Uptake in Macrophage Subtypes at the Single-Cell Level by LA-ICP-TOFMS Imaging
Schoeberl, A., Gutmann, M., Theiner, S., Schaier, M., Schweikert, A., Berger, W., & Koellensperger, G. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03442 · Cited by 33
Self-citationRevisiting metallodrugs for the treatment of skin cancers
Manzano, C. M., Nakahata, D. H., & de Paiva, R. E. F. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214506 · Cited by 32
Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor‐Associated Macrophages
Toupin, N. P., Herroon, M. K., Thummel, R. P., Turró, C., Podgorski, I., Gibson, H. M., & Kodanko, J. J. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202104430 · Cited by 33
Kowalski, K. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214996 · Cited by 30
Sahu, G., Patra, S. A., Pattanayak, P. D., Kaminsky, W., & Dinda, R. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c00326 · Cited by 30
Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy
Li, Z., Shen, Q., Mao, Z., & Tan, C. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200270 · Cited by 29
BQ-AurIPr: a redox-active anticancer Au( i ) complex that induces immunogenic cell death
Mule, R. D., Kumar, A., Sancheti, S. P., Senthilkumar, B., Kumar, H., & Patil, N. T. (2022) · Chemical Science · doi:10.1039/d2sc03756d · Cited by 31
Guan, Q.-Y., Lin, Y.-R., Li, L., Tang, Z.-M., Zhao, X., & Shi, J. (2021) · Foods · doi:10.3390/foods10112788 · Cited by 29
“This system coordinates with other systems in the body to maintain the vital stability of the internal environment and physiological balance [16,17].”
BackgroundBiegański, P., Godel, M., Riganti, C., Kawano, D. F., Kopecka, J., & Kowalski, K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105514 · Cited by 28
Chemopreventive Potential of Dietary Nanonutraceuticals for Prostate Cancer: An Extensive Review
Chopra, H., Bibi, S., Goyal, R., Gautam, R. K., Trivedi, R., Upadhyay, T. K., Mujahid, M. H., Shah, M. A., Haris, M., Khot, K. B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925379 · Cited by 32
Lim, Y. Y., Zaidi, A. M. A., & Miskon, A. (2023) · Molecules · doi:10.3390/molecules28072920 · Cited by 28
“These modifications aim to restore the main mechanisms of trigger signals that induce the organic compound reactions in cell apoptosis [89,90].”
BackgroundÁlvarez, N., Viña, D., Leite, C. M., Mendes, L. F. S., Batista, A. A., Ellena, J., Costa-Filho, A. J., & Facchin, G. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110930 · Cited by 28
Photo-Activated Ferrocene-Iridium(III) Prodrug Induces Immunogenic Cell Death in Melanoma Stem Cells
Lie, Q., Jiang, H., Lu, X., Chen, Z., Liang, J., Zhang, J., & Chao, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00533 · Cited by 30
Fluorinated-NHC Transition Metal Complexes: Leading Characters as Potential Anticancer Metallodrugs
Rufino‐Felipe, E., Colorado‐Peralta, R., Reyes‐Márquez, V., Valdés, H., & Morales‐Morales, D. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200908103452 · Cited by 28
Gambino, D., & Otero, L. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2021.816266 · Cited by 27
Jia, S., Wang, R., Wu, K., Jiang, H., & Du, Z. (2019) · Molecules · doi:10.3390/molecules24030581 · Cited by 26
“Au compounds can be considered as prodrugs, and require activation (achieved by ligand exchange reactions) before they can develop their full pharmacological potential [29].”
BackgroundAjibade, P. A., Andrew, F. P., Fatokun, A. A., & Oluwalana, A. E. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.129894 · Cited by 25
Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy
Wang, Y., Wang, B., Li, K., Wang, M., & Xiao, H. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100276 · Cited by 28
“Half-Sandwich” Ruthenium Complexes with Alizarin as Anticancer Agents: In Vitro and In Vivo Studies
Honorato, J., Guedes, A. P. M., Leite, C. M., Moraes, C. A. F., Santos, A. L., Brito, R. D. S., Rocha, T. L., Mello-Andrade, F., Ellena, J., & Batista, A. A. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c00183 · Cited by 27
Ai, Y., Zhang, Z., Fei, Y., Ye, R., Law, A. S., Mao, Z., Liu, J., Li, Y., & Yam, V. W. (2023) · Science China Chemistry · doi:10.1007/s11426-023-1702-x · Cited by 24
Targeted Therapeutic-Immunomodulatory Nanoplatform Based on Noncrystalline Selenium
Chen, Q., Liu, T., Chen, S., Luo, Y., Ma, M., Xue, F., Zhang, L., Bao, W., & Chen, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b15774 · Cited by 24
Ok, K., Filipović, M. R., & Michel, S. L. J. (2021) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202100402 · Cited by 24
Liu, X., Sheng, S., Yang, H., He, Z., Yang, Y., Sheng, N., Fang, H., & Shi, G. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c09309 · Cited by 23
Metallomics and other omics approaches in antiparasitic metal-based drug research
Scalese, G., Kostenkova, K., Crans, D. C., & Gambino, D. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102127 · Cited by 23
Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination
Lv, X., Huang, J., Min, J., Wang, H., Xu, Y., Zhang, Z., Zhou, X., Wang, J., Liu, Z., & Zhao, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.078 · Cited by 23
Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma
Yuan, Y., Wu, D., Li, J., Huang, D., Zhao, Y., Gao, T., Zhuang, Z., Cui, Y., Zheng, D., & Ying, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1217400 · Cited by 29
“M1-TAMs are mainly present in the tumor adjacent tissue, while M2-TAMs are mainly present in the liver cancer tissue (Luo et al., 2017; Englinger et al., 2019).”
BackgroundChallenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs
Poetsch, I., Baier, D., Keppler, B. K., & Berger, W. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016452-00308 · Cited by 26
Self-citationSánchez‐Mora, A., Valdés, H., Ramírez‐Apán, M. T., Nieto‐Camacho, A., Hernández‐Ortega, S., Canseco‐González, D., & Morales‐Morales, D. (2019) · Inorganica Chimica Acta · doi:10.1016/j.ica.2019.119061 · Cited by 22
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Tonon, G., Rizzolio, F., Visentin, F., & Scattolin, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168651 · Cited by 25
“…(i) the use of ligands firmly anchored to the metal center (e.g., organometallic fragments and/or chelating ligands) [57–59], and (ii) conjugation to molecular targeting agents such as monoclonal antibodies [60], estrogen receptor antagonists [61,62], and immune checkpoint inhibitors [63,64].”
BackgroundYang, J., Wang, F., Huang, S., Feng, T., Xiong, K., Chen, Y., & Chao, H. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202505689 · Cited by 21
Thanh, N. T., Pham, V. T., & Huynh, H. V. (2020) · Organometallics · doi:10.1021/acs.organomet.0c00450 · Cited by 21
Li, W., Li, S., Man, X., Xu, G., Zhang, Z., Zhang, Y., Liang, H., & Yang, F. (2024) · Rare Metals · doi:10.1007/s12598-024-02871-x · Cited by 26
“Accumulating evidence indicates that many conventional chemotherapeutic drugs not only kill cancer cells directly based on their cytotoxicity but also achieve it by activating the tumor’s immune system [23, 24].”
DNA or not DNA —that is the question determining the design of platinum anticancer drugs
Jin, S., Feng, C., & Wang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117077 · Cited by 22
Platinum(IV) Complexes Trigger Death Receptors and Natural Killer Cells to Suppress Breast Cancer
Cai, L., Chen, H., Wang, Y., Zhang, G., Song, D., Tan, Y., Guo, Z., & Wang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02509 · Cited by 20
Li, S., Yuan, H., Yang, X., Xu, X., Yu, W., Wu, Y., Yao, S., Xie, J., He, W., Guo, Z., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.4c02156 · Cited by 21
Shee, M., Zhang, D., Banerjee, M., Roy, S., Pal, B., Anoop, A., Yuan, Y., & Singh, N. D. P. (2023) · Chemical Science · doi:10.1039/d3sc03096b · Cited by 20
Tabrizi, L., Nguyen, T. L. A., & Dao, D. Q. (2019) · RSC Advances · doi:10.1039/c9ra02726b · Cited by 20
El‐Shafai, N. M., Farrag, F. A., Shukry, M., Mehany, H. M., Aboelmaati, M. G., AbuAli, O., Saleh, D. I., Ramadan, M., & El‐Mehasseb, I. M. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-02994-7 · Cited by 21
Albumin-targeted oxaliplatin( iv ) prodrugs bearing STING agonists
Dijkstra, M., Gutmann, M., Gradl, M., Federa, A., Jaunecker, C., Breitenstein, J. V., Vician, P., Pirker, C., Valcanover, D., Heffeter, P., et al. (2025) · Inorganic Chemistry Frontiers · doi:10.1039/d5qi00433k · Cited by 21
Self-citationGold Nanoparticles Dissolve Extracellularly in the Presence of Human Macrophages
McCarrick, S., Midander, K., Krausová, M., Carlander, U., & Karlsson, H. L. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s314643 · Cited by 19
Rudbari, H. A., Saadati, A., Aryaeifar, M., Blacque, O., Cuevas, J. V., Cabral, R., Raposo, L. R., & Fernandes, A. R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105556 · Cited by 19
Rahmanian, M., Oroojalian, F., Pishavar, E., Kesharwani, P., & Sahebkar, A. (2023) · European Polymer Journal · doi:10.1016/j.eurpolymj.2023.112215 · Cited by 20
Rational approaches towards inorganic and organometallic antibacterials
Hess, J. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0253 · Cited by 19
Novohradský, V., Marková, L., Kostrhunová, H., Kašpárková, J., Hoeschele, J. D., & Brabec, V. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111628 · Cited by 19
Passeri, G., Northcote‐Smith, J., & Suntharalingam, K. (2022) · RSC Advances · doi:10.1039/d1ra08788f · Cited by 19
Doroudian, M., & Gailer, J. (2022) · Inorganics · doi:10.3390/inorganics10110200 · Cited by 22
Platinum(IV)-based prodrugs as an alternative to Pt(II)-based drugs: synthesis and biological action
Spector, D. V., Bubley, A., Beloglazkina, E. K., & Krasnovskaya, O. O. (2023) · Russian Chemical Reviews · doi:10.59761/rcr5096 · Cited by 19
A multifaceted approach towards organometallic anticancer agent development
Hartinger, C. G. (2024) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2024.123144 · Cited by 20
Biological activity of vanadium pincer complexes
Delgado-Rangel, L. H., Reyes‐Márquez, V., Moreno-Narváez, M. E., Aragón-Muriel, A., Parra-Unda, J. R., Cruz-Navarro, J. A., Martínez-Torres, M. A., Valdés, H., & Morales‐Morales, D. (2024) · New Journal of Chemistry · doi:10.1039/d4nj04551c · Cited by 19
Gold‐Ions‐Mediated Diproline Peptide Nanocarpets and Their Inhibition of Bacterial Growth
Singh, R. S., Suryavashi, V., Vinayak, V., & Joshi, K. B. (2019) · ChemistrySelect · doi:10.1002/slct.201900847 · Cited by 18
Ortega, E., Ballester, F. J., Hernández-García, A., Hernández‐García, S., Guerrero‐Rubio, M. A., Bautista, D. K. M., Santana, M. D., Gandía‐Herrero, F., & Ruiz, J. (2020) · Inorganic Chemistry Frontiers · doi:10.1039/c9qi01704f · Cited by 18
Synthesis, Structure, and Antiproliferative Action of 2-Pyridyl Urea-Based Cu(II) Complexes
Geyl, K. K., Baykov, S. V., Kalinin, S., Bunev, A. S., Troshina, M. A., Sharonova, T. V., Skripkin, M. Y., Kasatkina, S. O., Presnukhina, S. I., Шетнев, А. А., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020461 · Cited by 19
Chromium Nanoparticles Improve Macrophage and T Cell Infiltration for Cancer Immunotherapy
Liu, Q., Sun, Z., Duo, Y., Yin, L., Lv, K., Yue, L., Meng, Q., Nie, D., Chen, J., Luo, D., et al. (2023) · ACS Materials Letters · doi:10.1021/acsmaterialslett.2c01136 · Cited by 17
Wang, M., Li, G., Jiang, G., Cai, J., Zhong, W., Huang, R.-Z., Liu, Z., Huang, X., & Wang, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116095 · Cited by 17
Xu, B.-B., Jin, N., Liu, J.-C., Liao, A.-Q., Lin, H.-Y., & Qin, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02432 · Cited by 17
Chen, X., Peng, K., Chen, X., Pan, Z., Shen, Q., Ling, Y., Zhao, J., & Tan, C. (2024) · Aggregate · doi:10.1002/agt2.623 · Cited by 17
Karges, J., Chao, H., & Gasser, G. (2020) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202000545 · Cited by 18
Hu, X., Sun, F., Zhu, C., Yáng, Z., & Huang, W. (2022) · Nano Research · doi:10.1007/s12274-022-5145-1 · Cited by 19
Liu, Z., Lin, X., Wang, H., & Zhang, P. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216969 · Cited by 17
Łyczko, K., Pogorzelska, A., Częścik, U., Koronkiewicz, M., Rode, J. E., Bednarek, E., Kawęcki, R., Węgrzyńska, K., Baraniak, A., Milczarek, M., et al. (2024) · RSC Advances · doi:10.1039/d4ra03141e · Cited by 16
Jain, S., Bhar, K., Bandyopadhayaya, S., Singh, V. K., Mandal, C. C., Tapryal, S., & Sharma, A. K. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111174 · Cited by 16
Bioactive half-sandwich Rh and Ir bipyridyl complexes containing artemisinin
Chellan, P., Avery, V. M., Duffy, S., Land, K. M., Tam, C. C., Jong Heon, K. I. M., Cheng, L. W., Romero‐Canelón, I., & Sadler, P. J. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111408 · Cited by 17
Tham, M. J. R., Babak, M. V., & Ang, W. H. (2020) · Angewandte Chemie · doi:10.1002/ange.202008604 · Cited by 17
Platinum-based Cancer Chemotherapeutics: Recent Trends and Future Perspectives
Parveen, S. (2022) · Current Chinese Science · doi:10.2174/2210298102666220404102936 · Cited by 15
Castro, F. D., Stefàno, E., Luca, E. D., Benedetti, M., & Fanizzi, F. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030941 · Cited by 15
Wang, F.-Y., Yang, L.-M., Xiong, X.-L., Yang, J., Yang, Y., Tang, J.-Q., Gao, L., Lu, Y., Wang, Y., Zou, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00583 · Cited by 15
Sarpong‐Kumankomah, S., & Gailer, J. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200628023540 · Cited by 15
Gascón, E., Otal, I., Maisanaba, S., Llana‐Ruíz‐Cabello, M., Valero, E., Repetto, G., Jones, P. G., Oriol, L. T., & Jiménez, J. (2022) · Dalton Transactions · doi:10.1039/d2dt01963a · Cited by 15
Exploring the Potential of Metal‐Based Candidate Drugs as Modulators of the Cytoskeleton
Borutzki, Y., Skos, L., Gerner, C., & Meier, S. M. (2023) · ChemBioChem · doi:10.1002/cbic.202300178 · Cited by 17
Abdulameer, J. H., & Alias, M. F. A. (2022) · Baghdad Science Journal · doi:10.21123/bsj.2022.7178 · Cited by 15
Wang, J.-Q., Liu, X., Zhu, Z.-S., Li, Z., Xie, C., Qiao, X., Feng, Y., & Xu, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00352 · Cited by 16
Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours
Farrer, N. J., Higgins, G. S., & Kunkler, I. H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01746-1 · Cited by 14
“This may also potentially increase the immunostimulatory effects of RT [17], since the use of platinum [18] or PARP prodrugs is likely to increase the amount of DNA damage, micronuclei formation and cyclic GMP-AMP synthase (cGas) activation [19], which may subsequently increase the immunotherapy response.”
BackgroundCopper( ii ) curcumin complexes for endoplasmic reticulum targeted photocytotoxicity
Banaspati, A., Ramu, V., Raza, M. K., & Goswami, T. K. (2022) · RSC Advances · doi:10.1039/d2ra04813b · Cited by 15
Yang, S. M., Kim, J.-E., Lee, J.-Y., Lee, J., & Lee, J. M. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0029 · Cited by 15
“Current cancer treatments encompass a range of approaches, including hormone therapy, surgery, bone marrow transplantation, chemotherapy, radiotherapy, targeted therapy, and immunotherapy (32).”
BackgroundDas, A., & Sankaralingam, M. (2023) · Dalton Transactions · doi:10.1039/d3dt02419a · Cited by 14
Natural products as potential drug treatments for acute promyelocytic leukemia
Chen, J., & Ding, Z. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00928-8 · Cited by 16
“Of these, As (V) is less toxic, and its biological activity is based primarily on phosphate substitu-tion [25].”
BackgroundSun, D. L., Poddar, S., Pan, R. D., Rosser, E. W., Abt, E. R., Valkenburgh, J. S. V., Le, T. M., Lok, V. M., Hernandez, S., Song, J., et al. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00594c · Cited by 15
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.